Barbara Saxty, a Drug Discovery Manager in MRC Technology’s Assay Development and Screening Group, has co-authored a paper published today (21st February 2012) in Nature Communications.

The paper, entitled An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid, can be found on the Nature Communications website.

« Back to news